Mirimus has harnessed the power of CRISPR-Cas9 to create a novel platform for the generation of designer models by introducing specific genetic alterations in mouse models.
Animal models are the gold standard for dissecting disease mechanisms; however, the cost and long lead time to develop them has prevented their routine use in research. The advent of CRISPR/Cas9 genome editing, enables us to genetically engineer and study human diseases in mice.
Mirimus, together with Charles River Laboratories, provides end-to-end service, beginning with model design, molecular engineering expertise, CRISPR/Cas9 genome engineering and RNAi technologies, and full embryology services. Clients can tap into Mirimus experts in creation of RNAi and CRISPR/Cas9 mouse models for pre-clinical research models that will pave the way toward our understanding of disease pathogenesis and bring us better, faster cures.
Mirimus has harnessed the power of CRISPR-Cas9 to create a novel platform for the generation of designer models by introducing specific genetic alterations in mouse models.
Animal models are the gold standard for dissecting disease mechanisms; however, the cost and long lead time to develop them has prevented their routine use in research. The advent of CRISPR/Cas9 genome editing, enables us to genetically engineer and study human diseases in mice.
Mirimus, together with Charles River Laboratories, provides end-to-end service, beginning with model design, molecular engineering expertise, CRISPR/Cas9 genome engineering and RNAi technologies, and full embryology services. Clients can tap into Mirimus experts in creation of RNAi and CRISPR/Cas9 mouse models for pre-clinical research models that will pave the way toward our understanding of disease pathogenesis and bring us better, faster cures.
Let us guide you through this journey, every step of the way.